Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

Speakers from Almirall, AstraZeneca, Bayer, BioNTech, Glenmark, and GSK share innovative approaches to drive commercial excellence BARCELONA, Spain, Oct. 29, 2024 /PRNewswire/ -- Veeva ...

Veeva Systems (NYSE: VEEV) today announced that leaders from Almirall, AstraZeneca, Bayer AG, BioNTech SE, Glenmark, and GSK ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work of a team ...

GSK is also seeking damages to compensate for the alleged infringement as well as a “compulsory ongoing licensing fee” for the claimed technologies. “Moderna has reaped billions of dollars in revenue ...

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.

By Blake Brittain (Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

According to GSK, as much as 4% of the general population is affected by the condition, which can be associated with asthma and allergic rhinitis. Dupixent, which has become one of the pharmaceutical ...